A two-part, phase 1 open label, dose escalaltion and expansion study to assess safety, pharmacokinetics and clinical activity of NUC3373, a nucleotide analogue, in participants with advanced solid tumours

Trial Profile

A two-part, phase 1 open label, dose escalaltion and expansion study to assess safety, pharmacokinetics and clinical activity of NUC3373, a nucleotide analogue, in participants with advanced solid tumours

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Nov 2016

At a glance

  • Drugs NUC 3373 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Apr 2016 Trial design presented at the 107th Annual Meeting of the American Association for Cancer Research
    • 17 Mar 2016 Status changed from planning to recruiting as per United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top